Edwards Lifesciences (NYSE:EW) is poised to take the lead in the transcatheter aortic valve market with its Sapient 3 replacement heart valve, according to Leerink Partners analyst Danielle Antalffy.
Writing yesterday in a note to investors following the annual London Valve meeting, Antalffy said physicians there surveyed as part of Leerink’s Medacorp program told her that the Sapien 3, notwithstanding newer TAVI offerings from rivals Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and Direct Flow Medical.
“Even with the promise of MDT’s Evolut R, all 4 physicians unanimously agreed that EW’s next-gen Sapien 3 is the best valve on the market.
Help employers find you! Check out all the jobs and post your resume.
